Bionano Genomics (NASDAQ:BNGO) is a commercial-stage genomics analysis company focused on advancing research and clinical applications through high-resolution genome mapping. Founded in the mid-2000s and headquartered in San Diego, California, the company developed its flagship Saphyr® system to empower scientists and clinicians with detailed structural insight into DNA molecules. Bionano’s mission centers on enabling the discovery of previously inaccessible genomic variations, particularly in areas such as rare disease, oncology and agricultural biotechnology.
The company’s core offering, the Saphyr system, combines specialized reagents, chip consumables and proprietary software to deliver ultra-long DNA molecule imaging and analysis. Saphyr is designed to detect large structural variants, copy number variations and complex rearrangements with high sensitivity. In addition to instruments and consumables, Bionano operates a service bureau, providing contract research and custom analysis for pharmaceutical companies, academic institutions and diagnostic laboratories seeking targeted or discovery-driven genome mapping solutions.
Bionano’s technologies are utilized by a global customer base that spans North America, Europe, Asia and Latin America. The platform has been adopted in collaborative programs with leading research centers, biopharma organizations and healthcare providers, driving initiatives in precision medicine, translational research and agricultural genomics. The company also collaborates with regulatory bodies and academic consortia to advance standards for structural variant characterization and reporting.
Led by President and CEO Erik Holmlin and supported by a board of directors with deep expertise in biotechnology and life-science instrumentation, Bionano Genomics leverages its scientific advisory panel and experienced management team to guide product development and market expansion. The company completed its initial public offering in 2018 and continues to invest in R&D, aiming to broaden the accessibility of genome mapping and to accelerate discoveries across research and clinical communities worldwide.
